|
NLS Pharmaceutics AG (NLSP) DCF تقييم
CH | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
NLS Pharmaceutics AG (NLSP) Bundle
تبحث لتقييم القيمة الجوهرية لـ NLS Pharmaceutics AG؟ يدمج حاسبة DCF (NLSP) DCF بيانات العالم الحقيقي مع ميزات تخصيص واسعة ، مما يتيح لك تحسين التوقعات وتعزيز استراتيجيات الاستثمار الخاصة بك.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -.4 | .0 | -11.9 | -15.5 | -11.8 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | 4.2 | 2.3 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -4.6 | -2.3 | -11.9 | -15.5 | -11.8 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | .2 | .1 | 5.4 | 8.9 | .9 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | -.1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 2.5 | 4.0 | 1.7 | 2.4 | 4.6 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -4.6 | -2.3 | -11.9 | -15.5 | -11.8 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 2.0 | 1.6 | -14.2 | -14.8 | -9.6 | -4.6 | .0 | .0 | .0 | .0 |
| WACC, % | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -4.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -4 | |||||||||
| Net Debt | 1 | |||||||||
| Equity Value | -5 | |||||||||
| Diluted Shares Outstanding, MM | 38 | |||||||||
| Equity Value Per Share | -0.13 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real NLS Pharmaceutics AG (NLSP) financials.
- Real-World Data: Historical data and forward-looking estimates (as highlighted in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe the effect of your inputs on NLS Pharmaceutics AG (NLSP) valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive NLSP Data: Pre-loaded with NLS Pharmaceutics AG's historical financial metrics and future projections.
- Customizable Financial Inputs: Modify revenue growth rates, profit margins, discount rates, tax assumptions, and capital expenditures.
- Interactive Valuation Model: Automatic recalculation of Net Present Value (NPV) and intrinsic value based on your specified inputs.
- Multiple Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation results.
- Intuitive User Interface: Designed for ease of use, catering to both industry professionals and newcomers.
How It Works
- Step 1: Download the Excel file for NLS Pharmaceutics AG (NLSP).
- Step 2: Review the pre-filled financial data and forecasts for NLS Pharmaceutics AG (NLSP).
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment strategies.
Why Choose This Calculator?
- Accurate Data: Real NLS Pharmaceutics AG (NLSP) financials ensure reliable valuation results.
- Customizable: Adjust key parameters like growth rates, WACC, and tax rates to align with your projections.
- Time-Saving: Pre-built calculations save you from starting from scratch.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants.
- User-Friendly: Intuitive layout and step-by-step instructions make it accessible for all users.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling NLS Pharmaceutics AG (NLSP) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for NLS Pharmaceutics AG (NLSP).
- Consultants: Deliver professional valuation insights on NLS Pharmaceutics AG (NLSP) to clients quickly and accurately.
- Business Owners: Understand how biotech companies like NLS Pharmaceutics AG (NLSP) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to NLS Pharmaceutics AG (NLSP).
What the Template Contains
- Historical Data: Includes NLS Pharmaceutics AG’s (NLSP) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate NLS Pharmaceutics AG’s (NLSP) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of NLS Pharmaceutics AG’s (NLSP) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.